Evidence map›Paper›PMID 37971519›Full record

ArticlePediatric nephrology (Berlin, Germany)2024

Long-term kidney outcomes in pediatric continuous-flow ventricular assist device patients.

Alexandra Idrovo, Seth A Hollander, Tara M Neumayr, Cynthia Bell, Genevieve Munoz, Swati Choudhry, Jack Price, Iki Adachi, Poyyapakkam Srivaths, Scott Sutherland and 1 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Pediatric nephrology (Berlin, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Alexandra IdrovoRenal Section, Department of Pediatrics, Baylor College of Medicine, Texas Children's, Houston, TX, USA. Alexandra.Idrovo@UTSouthwestern.edu.ORCID 0009-0009-2897-840X
Seth A HollanderDivision of Cardiology, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA, USA.
Tara M NeumayrDivision of Pediatric Critical Care Medicine, Department of Pediatrics, Washington University School, St. Louis, MO, USA.
Cynthia BellMcGovern Medical School, University of Texas Health Science Center, Houston, TX, USA.
Genevieve MunozDivision of Pediatric Critical Care Medicine, Department of Pediatrics, Washington University School, St. Louis, MO, USA.
Swati ChoudhryPediatrics, Cardiology Section, Baylor College of Medicine/Texas Children's, Houston, TX, USA.
Jack PricePediatrics, Cardiology Section, Baylor College of Medicine/Texas Children's, Houston, TX, USA.
Iki AdachiDivision of Congenital Heart Surgery, Department of Pediatrics, Baylor College of Medicine/Texas Children's, Houston, TX, USA.
Poyyapakkam SrivathsRenal Section, Department of Pediatrics, Baylor College of Medicine, Texas Children's, Houston, TX, USA.
Scott SutherlandDivision of Nephrology, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA, USA.
Ayse Akcan-ArikanRenal Section, Department of Pediatrics, Baylor College of Medicine, Texas Children's, Houston, TX, USA.
Baylor College of Medicine · USStanford University · USWashington University in St. Louis · USThe University of Texas Health Science Center at Houston · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundContinuous-flow ventricular assist devices (CF-VADs) are used increasingly in pediatric end-stage heart failure (ESHF) patients. Alongside common risk factors like oxidant injury from hemolysis, non-pulsatile flow constitutes a unique circulatory stress on kidneys. Post-implantation recovery after acute kidney injury (AKI) is commonly reported, but long-term kidney outcomes or factors implicated in the evolution of chronic kidney disease (CKD) with prolonged CF-VAD support are unknown.

methodsWe studied ESHF patients supported > 90 days on CF-VAD from 2008 to 2018. The primary outcome was CKD (per Kidney Disease Improving Global Outcomes (KDIGO) criteria). Secondary outcomes included AKI incidence post-implantation and CKD evolution in the 6-12 months of CF-VAD support.

resultsWe enrolled 134 patients; 84/134 (63%) were male, median age was 13 [IQR 9.9, 15.9] years, 72/134 (54%) had preexisting CKD at implantation, and 85/134 (63%) had AKI. At 3 months, of the 91/134 (68%) still on a CF-VAD, 34/91 (37%) never had CKD, 13/91 (14%) developed de novo CKD, while CKD persisted or worsened in 49% (44/91). Etiology of heart failure, extracorporeal membrane oxygenation use, duration of CF-VAD, AKI history, and kidney replacement therapy were not associated with different CKD outcomes. Mortality was higher in those with AKI or preexisting CKD.

conclusionsIn the first multicenter study to focus on kidney outcomes for pediatric long-term CF-VAD patients, preimplantation CKD and peri-implantation AKI were common. Both de novo CKD and worsening CKD can happen on prolonged CF-VAD support. Proactive kidney function monitoring and targeted follow-up are important to optimize outcomes.

Indexed as

Acute Kidney InjuryHeart-Assist DevicesHeart FailureRenal Insufficiency, ChronicAdolescentChildFemaleHumansKidneyMaleRetrospective StudiesTreatment OutcomeAKICKDContinuous-flow VADEnd-stage heart failureKidney outcomesMechanical circulatory supportVentricular assist device

Identifiers

PMID37971519
OpenAlexW4388724225

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.